SEO URLwww.firestrike.ai/deals/orbital-therapeutics-bristol-myers-squibb-acquisition-2026
acquisitionAnnounced · Feb 5, 2026ribonucleic acid medicationSource · CredibleArticle · Factual
Bristol-Myers Squibb acquires Orbital Therapeutics
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$1.5B
Target
Orbital Therapeutics
Cambridge, Massachusetts
Acquirer
Bristol-Myers Squibb
Full Acquisition
Status
Announced
Bristol-Myers Squibb agreed to acquire Orbital Therapeutics. Reported deal value: $1.5B. Status: Announced. Sector: ribonucleic acid medication. Target headquarters context: Cambridge, Massachusetts, United States.
This page summarizes publicly available information about the transaction as of 2026-02-05. Figures and status may change as filings and press coverage update.
Bailey Pemberton Bristol - Myers Squibb has agreed to acquire Orbital Therapeutics to expand its RNA -based therapies portfolio for cancer and autoimmune diseases
Deal timeline
Announced
Feb 5, 2026 · simplywall.st
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in ribonucleic acid medication with a reported deal value of $1.5B. Figures and status may change as sources update.
Sources: simplywall.st · Primary article · FireStrike proprietary index